The NGS-Based RNA-Sequencing Market size was estimated at USD 2.8 billion in 2023 and is projected to reach USD 6.5 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.70% during the forecast period (2024-2030).

NGS-Based RNA-Sequencing Market

Market Summary

The NGS-based RNA-sequencing market is a dynamic and rapidly evolving segment within the biotechnology industry, fundamentally transforming genomic research and clinical diagnostics. This technology enables comprehensive analysis of transcriptomes, providing unprecedented insights into gene expression, alternative splicing, and novel RNA discoveries. Its adoption is widespread across academic research institutions, pharmaceutical and biotechnology companies, and clinical laboratories, driven by the continuous demand for precise and high-throughput genetic data. The market is characterized by intense innovation, with key players constantly enhancing sequencing platforms, bioinformatics tools, and reagent kits to improve accuracy, reduce turnaround times, and lower operational costs. The integration of RNA-seq data with other multi-omics approaches is further expanding its utility in personalized medicine and complex disease research, solidifying its position as an indispensable tool in modern life sciences.

Key Highlights

The NGS-based RNA-sequencing market is distinguished by several key technological and application-based highlights. A primary highlight is the exceptional sensitivity and resolution of the technology, allowing for the detection of low-abundance transcripts and the identification of rare splice variants with high accuracy. The automation and scalability of modern RNA-seq workflows represent another significant advancement, enabling large-scale studies and population-level transcriptomic analyses. Furthermore, the continuous decline in sequencing costs per base pair has democratized access, allowing a broader range of organizations to leverage its power. The development of specialized protocols for challenging sample types, such as single-cell RNA-seq and spatial transcriptomics, has opened new frontiers in understanding cellular heterogeneity and tissue architecture. The robust ecosystem of data analysis software and cloud-based bioinformatics platforms is also a critical highlight, empowering researchers to manage and interpret the vast datasets generated efficiently.

Drivers, Opportunities & Restraints

The growth of the NGS-based RNA-sequencing market is propelled by a confluence of powerful drivers. The escalating focus on personalized medicine and the development of targeted therapeutics is a major force, as RNA-seq is crucial for biomarker discovery and understanding drug mechanisms. Significant investments in genomics research by both public and private entities worldwide further accelerate adoption. Technological advancements that consistently enhance sequencing throughput and data quality while reducing costs are fundamental drivers expanding the market's reach. The market presents substantial opportunities in clinical diagnostics, particularly in oncology for cancer subtyping and monitoring treatment response, and in infectious disease surveillance for pathogen characterization. However, the market faces notable restraints, including the high initial capital investment for sequencing instruments and the ongoing challenge of managing and analyzing the complex and voluminous data generated, which requires specialized bioinformatics expertise. Data standardization and the integration of results into clinical practice also present significant hurdles.

Concentration Insights

The competitive landscape of the NGS-based RNA-sequencing market is moderately concentrated, with a mix of established giants and innovative specialists. A handful of leading corporations, including Illumina, Thermo Fisher Scientific, and Pacific Biosciences, dominate the market for sequencing instruments and core consumables, leveraging their extensive intellectual property portfolios and global sales networks. This concentration is particularly evident in the high-throughput sequencing segment. However, the market also features a vibrant ecosystem of companies specializing in specific niches, such as sample preparation kits, library construction reagents, and advanced bioinformatics software solutions. Companies like Qiagen, Agilent Technologies, and 10x Genomics have carved out significant market shares with their specialized product offerings. This structure fosters a competitive environment where continuous innovation is essential, and partnerships between instrument manufacturers and specialty reagent or software providers are common to deliver integrated solutions to end-users.

Type Insights

The NGS-based RNA-sequencing market can be segmented by technology type, each catering to specific research needs. Bulk RNA-seq remains a widely used workhorse for profiling average gene expression across a population of cells, valued for its cost-effectiveness and well-established protocols. In contrast, single-cell RNA sequencing (scRNA-seq) has emerged as a transformative segment, enabling the dissection of transcriptional heterogeneity within tissues at an individual cell resolution. This has profound implications for developmental biology, immunology, and neurology. Another key segment is long-read sequencing technologies, offered by companies like Pacific Biosciences and Oxford Nanopore Technologies, which are adept at resolving complex transcript isoforms, full-length transcript sequencing, and detecting base modifications without the need for assembly. Each technology type offers distinct advantages, and the choice depends on the specific biological question, sample type, and required resolution.

Application Insights

The applications of NGS-based RNA-sequencing are vast and continually expanding, spanning both research and clinical domains. In drug discovery and development, it is indispensable for target identification, understanding compound toxicity, and stratifying patient populations for clinical trials. Within clinical diagnostics, its most prominent application is in oncology, for characterizing tumors, identifying fusion genes, and discovering predictive biomarkers for immunotherapy and targeted therapy. It is also increasingly applied in genetic disease research to identify causative mutations affecting RNA expression and splicing. In the field of agriculture and animal science, RNA-seq is used for crop improvement and livestock breeding by studying gene expression related to disease resistance and yield. Furthermore, it plays a critical role in basic research across all biological disciplines, from neuroscience to microbiology, fueling a continuous cycle of discovery.

Regional Insights

Geographically, the adoption and advancement of NGS-based RNA-sequencing are led by North America, which holds a significant market share. This leadership is attributed to the presence of a robust biotechnology and pharmaceutical sector, substantial government funding through agencies like the NIH, a high concentration of leading sequencing companies, and advanced healthcare infrastructure that facilitates translational research. Europe represents another major market, supported by strong academic research institutions and coordinated multinational genomic initiatives such as the Genome of Europe. The Asia-Pacific region is identified as the fastest-growing market, driven by increasing investments in genomics research by countries like China, Japan, and South Korea, expanding biotechnology capabilities, and a growing focus on precision medicine. Government initiatives aimed at building national genomic databases are significantly contributing to market growth in this region.

Company Insights

The competitive arena features a strategic interplay between dominant players and agile innovators. Illumina maintains a preeminent position with its comprehensive portfolio of sequencing systems, such as the NovaSeq and NextSeq series, and associated reagents. Thermo Fisher Scientific solidifies its standing with the Ion Torrent sequencing platform and its extensive suite of sample preparation and analysis solutions. Pacific Biosciences and Oxford Nanopore Technologies compete with their distinctive long-read sequencing technologies, which are gaining traction for specific RNA-seq applications. Beyond instrument manufacturers, companies like Qiagen and Agilent Technologies are key contributors, providing essential kits for RNA extraction, library preparation, and quality control. Bio-Rad Laboratories, through its acquisition of Celsee, and 10x Genomics are prominent forces in the single-cell analysis segment. The landscape is also populated by specialized bioinformatics firms like DNAnexus and Partek, which provide critical software for data analysis and interpretation.

Recent Developments

The NGS-based RNA-sequencing market is marked by a rapid pace of innovation and strategic activity. Recent developments have focused on enhancing the accessibility and clinical utility of the technology. Key players have launched new benchtop sequencers designed to offer high-quality data with simpler, more automated workflows, making the technology accessible to a wider range of laboratories. There has been a significant push towards the development and commercialization of IVD-approved kits and workflows, aiming to transition RNA-seq from a research tool to a routine clinical diagnostic application, particularly in oncology. Strategic partnerships and collaborations are frequent, often between sequencing companies and pharmaceutical firms to co-develop companion diagnostics. Furthermore, advancements in bioinformatics, including the integration of artificial intelligence and machine learning for data analysis, and the expansion of cloud-based genomic data platforms, represent critical recent progress in overcoming the data analysis bottleneck.

Report Segmentation

This comprehensive market research report on the NGS-Based RNA-Sequencing Market provides a detailed analysis structured across multiple segments to offer a granular view of the industry landscape. The report is meticulously segmented by technology type, delving into the nuances of bulk RNA-seq, single-cell RNA-seq, and long-read sequencing platforms. It further breaks down the market by product and service, covering instruments, consumables and reagents, and services including sequencing and bioinformatics. Application segmentation is thorough, encompassing key areas such as drug discovery, clinical diagnostics, agricultural biotechnology, and other research applications. The end-user segment analysis provides insights into demand from academic and research institutions, pharmaceutical and biotechnology companies, and clinical laboratories. Finally, the report offers a detailed geographical segmentation, providing market analysis for key regions including North America, Europe, Asia-Pacific, and the rest of the world, highlighting regional trends and growth potentials.

FAQs

What is NGS-based RNA-sequencing used for? NGS-based RNA-sequencing is primarily used to analyze the transcriptome, enabling researchers to quantify gene expression levels, discover novel genes and RNA variants, identify alternative splicing events, and detect fusion transcripts, with applications in basic research, drug discovery, and clinical diagnostics.

How much does RNA sequencing cost? The cost of RNA sequencing is variable and depends on factors such as sequencing depth, number of samples, library preparation method, and the choice of service provider or platform; however, costs have decreased significantly over time, making the technology more accessible.

What is the difference between DNA-seq and RNA-seq? DNA sequencing (DNA-seq) analyzes the genetic code stored in DNA to identify mutations and variations in the genome, while RNA sequencing (RNA-seq) analyzes the transcriptome to see which genes are actively being expressed and to what level in a specific cell or tissue at a given time.

What are the steps in RNA sequencing? The key steps in an RNA-seq workflow typically involve RNA extraction from samples, quality assessment, library preparation (which includes fragmentation, reverse transcription to cDNA, and adapter ligation), sequencing on an NGS platform, and finally, bioinformatics analysis of the generated data.

Which company is best for RNA sequencing? There is no single "best" company, as the choice depends on specific project requirements. Leading providers of instruments and services include Illumina, Thermo Fisher Scientific, and BGI, while companies like 10x Genomics specialize in single-cell RNA-seq solutions.

What is the principle of RNA sequencing? The principle involves converting a population of RNA into a library of cDNA fragments with adapters attached, sequencing these fragments using high-throughput next-generation sequencing technology, and then reassembling the sequences computationally to map them to a reference genome or transcriptome to determine abundance and identify variants.

Citius Research has developed a research report titled “NGS-Based RNA-Sequencing Market Report - Global Industry Analysis, Size, Share, Growth Trends, Regional Outlook, Competitive Strategies and Segment Forecasts 2024 - 2030” delivering key insights regarding business intelligence and providing concrete business strategies to clients in the form of a detailed syndicated report. The report details out the factors such as business environment, industry trend, growth opportunities, competition, pricing, global and regional market analysis, and other market related factors.

Details included in the report for the years 2024 through 2030

• NGS-Based RNA-Sequencing Market Potential
• Segment-wise breakup
• Compounded annual growth rate (CAGR) for the next 6 years
• Key customers and their preferences
• Market share of major players and their competitive strength
• Existing competition in the market
• Price trend analysis
• Key trend analysis
• Market entry strategies
• Market opportunity insights

The report focuses on the drivers, restraints, opportunities, and challenges in the market based on various factors geographically. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report. The NGS-Based RNA-Sequencing Market report is segmented on the basis of various market segments and their analysis, both in terms of value and volume, for each region for the period under consideration.

NGS-Based RNA-Sequencing Market Segmentation

Regions Covered

• North America
• Latin America
• Europe
• MENA
• Asia Pacific
• Sub-Saharan Africa and
• Australasia

NGS-Based RNA-Sequencing Market Analysis

The report covers below mentioned analysis, but is not limited to:

• Overview of NGS-Based RNA-Sequencing Market
• Research Methodology
• Executive Summary
• Market Dynamics of NGS-Based RNA-Sequencing Market
  • Driving Factors
  • Restraints
  • Opportunities
• Global Market Status and Forecast by Segment A
• Global Market Status and Forecast by Segment B
• Global Market Status and Forecast by Segment C
• Global Market Status and Forecast by Regions
• Upstream and Downstream Market Analysis of NGS-Based RNA-Sequencing Market
• Cost and Gross Margin Analysis of NGS-Based RNA-Sequencing Market
• NGS-Based RNA-Sequencing Market Report - Global Industry Analysis, Size, Share, Growth Trends, Regional Outlook, Competitive Strategies and Segment Forecasts 2024 - 2030
  • Competition Landscape
  • Market Share of Major Players
• Key Recommendations

The “NGS-Based RNA-Sequencing Market Report - Global Industry Analysis, Size, Share, Growth Trends, Regional Outlook, Competitive Strategies and Segment Forecasts 2024 - 2030” report helps the clients to take business decisions and to understand strategies of major players in the industry. The report delivers the market driven results supported by a mix of primary and secondary research. The report provides the results triangulated through authentic sources and upon conducting thorough primary interviews with the industry experts. The report includes the results on the areas where the client can focus and create point of parity and develop a competitive edge, based on real-time data results.

NGS-Based RNA-Sequencing Market Key Stakeholders

Below are the key stakeholders for the NGS-Based RNA-Sequencing Market:

• Manufacturers
• Distributors/Traders/Wholesalers
• Material/Component Manufacturers
• Industry Associations
• Downstream vendors

NGS-Based RNA-Sequencing Market Report Scope

COVID-19 Impact Analysis

Like most other markets, the outbreak of COVID-19 had an unfavorable impact on the NGS-Based RNA-Sequencing Market worldwide. This report discusses in detail the disruptions experienced by the market, the impact on flow of raw materials, manufacturing operations, production trends, consumer demand and the projected future of this market post pandemic.

The report has helped our clients:

• To describe and forecast the NGS-Based RNA-Sequencing Market size, on the basis of various segmentations and geography, in terms of value and volume
• To measure the changing needs of customers/industries
• To provide detailed information regarding the drivers, restraints, opportunities, and challenges influencing the growth of the market
• To gain competitive intelligence and uncover new opportunities
• To analyse opportunities in the market for stakeholders by identifying high-growth segments in NGS-Based RNA-Sequencing Market
• To strategically profile key players and provide details of the current competitive landscape
• To analyse strategic approaches adopted by players in the market, such as product launches and developments, acquisitions, collaborations, contracts, expansions, and partnerships

Report Customization

Citius Research provides free customization of reports as per your need. This report can be personalized to meet your requirements. Get in touch with our sales team, who will guarantee you to get a report that suits your necessities.

Frequently Asked Questions